What's new? Log in Free sign up

Delcath Systems (DCTH) News and press releases

Company Profile

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Delcath Systems, Maintains $17 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:DCTH) with a Buy and maintains $17 price target.

Earnings Scheduled For May 12, 2023

Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter.

Earnings Outlook For Delcath Systems

Looking Into Delcath Systems's Return On Capital Employed

HC Wainwright & Co. Maintains Buy on Delcath Systems, Lowers Price Target to $17

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and lowers the price target from $19 to $17.

12 Health Care Stocks Moving In Monday's Intraday Session

Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider.

Why Delcath Systems Shares Are Jumping Today

Biotech, Earnings, News, Health Care, Financing, Offerings, FDA, Movers, General

Delcath Systems Q4 EPS $(0.86) Misses $(0.76) Estimate, Sales $639.00K Miss $810.00K Estimate

Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.76) by 13.16 percent. This is a 24.64 percent decrease over losses of $(0.69) per share from

Delcath Systems Inked Deals To Secure Financing Up To $85M

News, Financing

Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the

The FDA Has Accepted Delcath Systems' New Drug Application Resubmission For HEPZATO Kit (Melphalan Hydrochloride For Injection/Hepatic Delivery System) Seeking Approval For Unresectable Hepatic-Dominant Metastatic Ocular Melanoma

News, Health Care, FDA, General

The FDA also communicated to Delcath that they consider the submission a complete class 2 response and the PDUFA date for the resubmission is August 14, 2023.

Press releases

From Benzinga Pro

Delcath Systems Provides Business Update and Reports Preliminary First Quarter 2023 Financial Results

Earnings, Press Releases

NEW YORK, May 12, 2023 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH) (Delcath or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,

Delcath Systems to Participate in the Lytham Partners Spring 2023 Investor Conference

NEW YORK, May 9, 2023 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will be participating in the Lytham

Delcath Systems to Host First Quarter 2023 Results

NEW YORK, May 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a

Delcath Systems Announces Resumption of Interest-Only Period for Company's Debt Facility

Amendment with Avenue Venture Opportunities Fund, L.P. provides for an interest-only period from March 31, 2023 to September 30, 2023 and defers $4.3 million in principal payments NEW YORK, April 3, 2023 /PRNewswire/ --

Delcath Systems Announces Closing of Private Placement of up to $85 Million

Led by Vivo Capital with participation from Logos Capital, BVF Partners LP, Stonepine Capital Management, LLC, Serrado Capital LLC and supported by existing investor, Rosalind Advisors $25 million financing upfront with

Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

Earnings, Press Releases

NEW YORK, March 27, 2023 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights

Delcath Systems Announces up to $85 Million Financing

Led by Vivo Capital with participation from Logos Capital, BVF Partners LP, Stonepine Capital Management, LLC, Serrado Capital LLC and supported by existing investor, Rosalind Advisors $25 million financing upfront with

Delcath Systems, Inc. Announces FDA Acceptance of New Drug Application Resubmission of Hepzato Kit with a PDUFA Date of August 14, 2023

NEW YORK, March 27, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the US Food and

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.